Five things for pharma marketers to know: Friday, December 14, 2018
Report: J&J knew for decades about asbestos in talc products; Court orders Purdue to release OxyContin marketing documents; FDA withdraws generic drug safety rule.
Most recent articles by Alison Kanski
Former staffer sues Navicor, top executives for sexual harassment, discrimination
The agency, parent company Syneos Health, and Navicor’s president and managing director were named as defendants.
Five things for pharma marketers to know: Wednesday, December 12, 2018
Obama, Democrats make final push for ACA signups; Lawmaker chastises Pfizer for resuming price increases; FDA declines Mallinckrodt’s abuse-deterrent opioid painkiller.
Merck names chief marketing, commercial officers
Vaccines head Michael Nally was named chief marketing officer at the pharma company.
Fishawack acquires creative marketing consultancy Blue Latitude Health
Fishawack is continuing to build out its U.S. footprint with this latest acquisition.
Five things for pharma marketers to know: Monday, December 10, 2018
Gilead names Roche veteran as CEO; Investigation into generic price fixing expands; Doctors, medical journals fail to disclose conflicts of interest.
Hill-Rom partners with EarlySense to create a smarter hospital bed
The “smart bed” could spur hospitals to market their own rooms to attract patients.
Shapiro, Peera named jury presidents for Cannes Lions
Robin Shapiro of TWBA/WorldHealth will lead the Pharma jury, while Shaheed Peera of Publicis LifeBrands will head up Health and Wellness
Analysts: Merck’s Gardasil undervalued by billions of dollars
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Xeomin launches campaign to end stigma against anti-aging injectables
Xeomin, made by Merz, is hoping to differentiate itself in a market dominated by Allergan’s Botox.
